Zinc deficiency aggravates abnormal glucose metabolism in thalassemia major patients.
BACKGROUND
The aim was to determine whether reduced serum zinc level has a contributory effect on impairment of insulin secretion in beta-thalassemic patients with transfusion-induced iron overload.


METHODS
Seventy thalassemia patients who received deferoxamine chelation therapy and 69 healthy individuals as the control group were evaluated. A standard oral glucose tolerance test (OGTT) was performed and blood samples for measurement of serum ferritin, zinc, and insulin concentrations were obtained.


RESULTS
Although the fasting serum insulin concentrations were quite similar between the patient and the control groups, serum insulin levels were significantly lower in the thalassemia patients one hour and two hours after oral glucose load ingestion compared with the healthy controls. Among the thalassemic adults, zinc deficiency (present in 37% of patients) resulted in significantly lower fasting and 1-hour post-OGTT serum insulin concentrations. The serum zinc level in patients with impaired OGTT was also considerably lower than in patients with normal OGTT.


CONCLUSIONS
These data support the assumption that zinc deficiency might lead to an exacerbation of the inability of the pancreas to secrete sufficient amounts of insulin in response to glucose stimulation in beta-thalassemia patients. We suggest that serum zinc levels be routinely monitored in these patients as it might provide useful complementaly information regarding glucose metabolism.
Dehshal
Mahmood Hadipour
MH
Iranian Thalassemia Society, Iran.
Hooghooghi
Amir Hooshang
AH
Kebryaeezadeh
Abbas
A
Kheirabadi
Morteza
M
Kazemi
Shahram
S
Nasseh
Azadeh
A
Shariftabrizi
Ahmad
A
Pasalar
Parvin
P
D000293:Adolescent; D000328:Adult; D002614:Chelating Agents / Q000627:therapeutic use; D003676:Deferoxamine / Q000627:therapeutic use; D005293:Ferritins / Q000097:blood; D005947:Glucose / Q000378:metabolism*; D005951:Glucose Tolerance Test; D006706:Homeostasis; D006801:Humans; D007328:Insulin / Q000378:metabolism*; D017262:Siderophores / Q000627:therapeutic use; D015032:Zinc / Q000097:blood / Q000172:deficiency; D017086:beta-Thalassemia / Q000188:drug therapy / Q000378:metabolism*
D002614:Chelating Agents; D007328:Insulin; D017262:Siderophores; D005293:Ferritins; D005947:Glucose; D003676:Deferoxamine; D015032:Zinc